AMGN Amgen

Q1 2025 10-Q

Filed: May 2, 2025Period ending Mar 31, 2025

Health Care

Biological Products, (No Diagnostic Substances)SEC EDGAR

Amgen (AMGN) 10-Q quarterly report for Q1 2025, filed with SEC EDGAR on May 2, 2025 for the fiscal period ending Mar 31, 2025. This page provides AI-powered analysis including management discussion & analysis (MD&A), risk factor updates, and key quarterly financial data such as revenue and net income extracted from XBRL.

AI Filing Analysis
Q1 2025 10-Q

Management Discussion & Analysis

• Revenue Prolia $1,099M, up 10% YoY from $999M
• U.S. Prolia sales $720M up 10%, ROW $379M up 11%

+3 more insights

Risk Factors

• New credit market risk triggered by COVID-19 and interest rate increases causing volatility and potential impairments in investment portfolio
• Market risk materially updated: asset impairments possible from inflation, credit downgrades, illiquidity, geopolitical events affecting investment values

+3 more insights

Quarterly Financial Summary
XBRL

Revenue

$8.1B

▲ +9.4% YoY

Net Income

$1.7B

▲ +1631.0% YoY

Operating Margin

14.5%

▲ +115bp YoY

Net Margin

21.2%

▲ +2275bp YoY

EPS (Diluted)

$3.20

▲ +1623.8% YoY

Operating Cash Flow

$1.4B

▲ +101.9% YoY

Source: XBRL data from Amgen Q1 2025 10-Q filing on SEC EDGAR. All figures in USD.

Other Amgen Quarterly Reports

Q3 2025 10-Q

Q2 2025 10-Q

Get deeper insights on Amgen

Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.